BFAR BioPharm Asia$0.19 Tradingchance auf 400-500%

Ticker: BFAR
Price: $0.19
Free Level2: http://www.otcmarkets.com/stock/BFAR/quote
Website: http://www.biopharmasiainc.com/
Share structue: Issued and Outstanding 50,000,000
Restricted  29,625,000 (59.25%)
Float 20,375,000 (40.75%)
Chart: http://stockcharts.com/freecharts/gallery.html?bfar



 

 

On March 25, 2011, China Northern Pharmacy Holding Group Limited, a wholly-owned subsidiary of BioPharm Asia, Inc. (the “Company”), entered into an agreement to transfer all of the outstanding shares of its subsidiary Tonghua S&T Medical & Pharmacy Company Limited (“PHARMACY”) and its subsidiary Yunnan Silin Pharmaceutical Company Limited (“Silin”) to City Well International Limited for RMB 200 million, or approximately $30.5 million, based upon prevailing exchange rates.

PHARMACY is an operating company engaged in drug logistics and distribution in the People’s Republic of China (“PRC”) which as of December 31, 2010 owned and operated 360 retail drug stores. In addition, PHARMACY owns 100% of Silin, a PRC company which is engaged in the sale of medicine products to hospitals and pharmacy shops. Management of PHARMACY and Silin had expressed displeasure at being a public company and the Company determined that it was in the interests of the Company’s shareholders to consummate the sale as described herein rather than continue the dispute with the disgruntled management and, potentially, lose the entire value of the operations of PHARMACY and Silin without receiving any compensation.

It is anticipated that the closing of the transfer will occur on or before April 1, 2011.

Management of the Company will seek to apply the net proceeds of the transaction to the acquisition of one or more new businesses.

Item 7.01 Regulation FD Disclosure.

On March 28, 2011, BioPharm Asia, Inc. (the “Company”), reported that it has entered into a letter of intent to acquire 100% of the outstanding shares of Hubei HolleyZhengyuan Pharmaceutical Company Limited ("HBHLZY"). HBHLZY, founded in November, 2004, is a wholesale distributor of pharmaceutical products, located at the CBD of Wuhan city, Hubei province.  

http://www.fixyou.co.uk/tracker_details.php?s=BFAR.PK  

 

BFAR - now we know where the selling pressure is coming from.

On March 25, 2011, China Northern Pharmacy Holding Group Limited, a wholly-owned subsidiary of BioPharm Asia, entered into an agreement to transfer all of the outstanding shares of its subsidiary Tonghua S&T Medical & Pharmacy Company Limited (PHARMACY), and its subsidiary Yunnan Silin Pharmaceutical Company Limited (Silin) to City Well International Limited for RMB 200 million, or approximately $30.5 million, based upon prevailing exchange rates.

PHARMACY is an operating company engaged in drug logistics and distribution in the People's Republic of China which as of December 31, 2010 owned and operated 360 retail drug stores. In addition, PHARMACY owns 100% of Silin, a PRC company which is engaged in the sale of medicine products to hospitals and pharmacy shops. Management of PHARMACY and Silin had expressed displeasure at being a public company and the Company determined that it was in the interests of the Company's shareholders to consummate the sale as described herein rather than continue the dispute with the disgruntled management and, potentially, lose the entire value of the operations of PHARMACY and Silin without receiving any compensation.

--

With the sale, BFAR sold all its wholesale and retail business. That leaves the company with approximately $46 million cash, its funny tree planting subsidiary, and the drug manufacturing.

If we take 2009 numbers, BFAR will lose 56% of its revenue with the sale of wholesale and retail operations. The chairman of BFAR is also chairman of PHARMACY, and he is the largest shareholder with 29.75%

--

So we have a company with $11M market cap and $46M cash that is under selling pressure most likely just because management of its main subsidiary "had expressed displeasure at being a public company" and forced re-privatization. Good chance we have our sellers here.

Very many unknowns at this point (how much cash will they have left when they found a replacement for their distribution and retail subs, the announcement today doesn't name a buy price), but given the facts the risk/reward ratio is very good here at $.25 - you can buy in at less than 1/4th cash value if we choose believe all of this.  

Hier findet Ihr Entry into a Material Definitive Agreement:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7821458

News vom 28.3.2011

BioPharm Asia in Negotiations to Acquire Hubei Holley Zhengyuan Pharmaceutical Company Limited

NEW YORK & TONGHUA, China, Mar 28, 2011 (BUSINESS WIRE) -- BioPharm Asia, Inc. (OTCBB: BFAR) (the "Company") announced today that it is negotiating to acquire a controlling interest in Hubei Holley Zhengyuan Pharmaceutical Company Limited ("HBHLZY").

HBHLZY, founded in November, 2004, is a wholesale distributor of pharmaceutical products, located at the CBD of Wuhan city, Hubei province. HBHLZY's facilities consist of packaging equipment and a logistical management system. HBHLZY sells 4580 types of products, from 652 suppliers in China and in particular, Hubei province. HBHLZY also acts as a sales agent for over 2000 types of products, including products from Shenzhen SanJiu Pharmaceutical Co., Ltd. and Shenzhen Zhijun Pharmaceutical Co., Ltd.

About BioPharm Asia, Inc.

BioPharm Asia, Inc. is engaged in the retail sale of medicinal and herbal products in China, complemented by vertically integrated supporting functions that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. Following several successful acquisitions, the Company is completing the integration of its distribution channels and expanding its trading business (conducted through its retail stores as well as its distribution activities) to include pharmaceutical manufacturing and the cultivation and sale of medicinal raw materials. The company has a plan to use the funds proceeds from sale of S&T and its subsidiary Silin to acquire HBHLZY. For more information, please visit http://www.biopharmasiainc.com.

Forward-looking statement: Except for certain historical information contained herein, the matters discussed in this news release contain forward-looking statements, including, but not limited to, statements relating to future acquisitions, expansion plans and growth in sales. These forward-looking statements involve a number of risks and uncertainties. Actual results may differ materially from those implied herein due to a number of factors, including, but not limited to, uncertainties in product demand, risks related to doing business in China, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors discussed in the company's most recent annual report and other filings with the U.S. Securities and Exchange Commission.

SOURCE: BioPharm Asia, Inc.

CONTACT:          

BioPharm Asia, Inc. Xia Yang Hu, 011-86-435-5211804 rodgerhu@biopharmasiaco.com

Copyright Business Wire 2011

-0-

KEYWORD:          United States
                 China
                 Asia Pacific
                 North America
                 New York
INDUSTRY KEYWORD: Health
                 Alternative Medicine
                 Biotechnology
                 Pharmaceutical
SUBJECT CODE:     Merger/Acquisition



Ein paar Infos zu der neuen Akquisition gibt es hier!

Shenzhen Zhijun Pharmaceutical Co.,Ltd 1company with 137.2Mil USD (RMB900Mill) assets, annual sales 182.93Mil USD (RMB1,200Mill). See profile below and from company website @http://szzhijun.com/english/about.aspx?id=25


Formerly named Shenzhen Pharmaceutical Factory, Shenzhen Zhijun Pharmaceutical. Co.ltd was established in 1985, playing a key role in SINOPHARM cephalosporin manufacturing lineup and also representing the core manufacturing enterprise in Shenzhen Accord Pharm.

With over 20 years’ endeavor, Zhijun has developed into a national High-Tech Enterprise focusing on Quality, Efficiency and Technology, with total assets equal to RMB900 million, annual turnover reach RMB1,200 million, and annual interest duty over RMB 100million. Now Zhijun has grown to a National Hi-Tech Enterprise among the list of Top 50 Pharmaceutical Factory in China.

Zhijun is strong in manufacturing Respiratory and Anti-infective pharmaceutical products, owns an international standardized R&D premise of 45,000 square kilometers, 9 production lines within 5 workshops which are powder for injection, oral solution and oral solid ( for cephalosporins and non-cephalosporins ). The company is in line with the EU GMP quality management, produced a series of market leading products with stringent quality control and management system and powerful marketing network. DaliXin (Cefuroxime axetil tablets and capsules) is the best player, leading the Dali brand and Zhijun brand to the top of the marketplace. The company is expanding the business in overseas markets and building strong reputation profile in global marketplace.

The Zhijun Product line has extended to the healthcare and OTC products. In the near future, Zhijun Pharma will take advantage of the SINOPHARM manufacture and sales integration, combine the API supplying to reduce the production cost and expand the scale, thus driving itself to be the core enterprise in the China Pharmaceutical Group Manufacturing lineup.  

Hubei Holley Zhengyuan Pharmaceutical Co., Ltd. operates as a pharmaceutical distributor. The company is based in Wuhan, China. Hubei Holley Zhengyuan Pharmaceutical Co., Ltd. operates as a subsidiary of Beijing Holley Jiuzhou Pharmaceutical Co. Ltd. As per the transaction announced on December 10, 2008, Hubei Holley Zhengyuan Pharmaceutical Co., Ltd. operates as a subsidiary of Wuhan Jianmin Pharmaceutical Group Co. Ltd.
No.7032 Dong Xihu Ave.
Dong Xihu Dist.
Wuhan, 430040
China  

 

der key player bei BFAR ist aktuell HDSN!
Ist dieser von der Ask Seite außer Reichweite dürfe es hier zu einem größeren Run auf die Aktie kommen.  

As previously reported in our Current Report on Form 8-K filed on February 14, 2011, we have engaged Acquavella, Chiarelli, Shuster, Berkower & Co. LLP (the “New Accountant”) to audit our financial statements to be included in our Annual Report on Form 10-K for the year ended December 31, 2010 (the “2010 Form 10-K”), which will include our financial statements as at December 31, 2009 and 2010 and the years then ended, and the audit report of the New Accountant thereon.  Following the filing of the 2010 Form 10-K and after the inclusion therein of the audit report of the New Accountant on our financial statements as at and for the year ended December 31, 2009, we will file a further amendment to our 2009 Form 10-K to include the audit report of the New Accountant on our financial statements as at and for the year ended December 31, 2009.

Source: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7785655  

Item 4.01. Changes in Registrant's Certifying Accountant.

Resignation of Principal Accountant

1.   By letter dated January 20, 2011, BioPharm Asia, Inc. (the “Company”) advised Etania Audit PC (formerly known as Davis Accounting Group PC) that it had been terminated as the independent registered public accounting firm for the Company.  The Company initially engaged Davis Accounting Group P.C. on February 21, 2010.

2.    Etania Audit PC issued an audit report on the consolidated financial statements of the Company as at and for the years ended December 31, 2009 and 2008, which did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles. In connection with the audit of the consolidated financial statements of the Company as at and for the years ended December 31, 2009 and 2008 and through the date of this Current Report: (i) there were no disagreements between the Company and Etania Audit PC on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Etania Audit PC, would have caused Etania Audit PC  to make reference to the subject matter of the disagreement in its report on the Company's financial statements for such year or during the interim period through the date of this Report, and (ii) there were no reportable events within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K

3.    The termination of Etania Audit PC was approved by the Board of Directors of the Company on January 6, 2011.

4.    The Company has provided Etania Audit PC a copy of the disclosures in this Form 8-K and has requested that Etania Audit PC furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not Etania Audit PC agrees with the Company's statements in this Item 4.01.  A copy of the letter to be furnished by Etania Audit PC in response to that request will be filed as an exhibit to this Form 8-K by an amendment to this Form 8-K.

Item 9.01 Financial Statements and Exhibits
(d) Exhibits

 http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7668618  

1. Kurs aktuell $0.17 +$0.005  

charttechnisch könnte es heute zum Turnaround kommen.
Bollinger Band dreht nach oben und der MFI und MACD sind sowieso schon positiv...

 

 

 

http://www.sec.gov/Archives/edgar/data/1080908/...09001507/ex99-1.htm  

Der Accum Dist. Indikator hat mit dem gestrigen Handelsverlauf seinen Fall ins Bodenlose gestoppt. Könnte ein Anzeichen für den Turnaround sein...  

Fullstochastic hat auch ein Kaufsignal gegeben...  

 

Heute könnte wir die erste grüne Kerze nach 10 roten Kerzen in Folge sehen.
Aktueller Kurs steht bei $0.141 zu $0.15
Denke wir werden hier in kürzester Zeit einen Shortsqueeze sehen.  

 

BFAR $0.14 a lot of eyes watching this. Today there is a very big chance we could see the turnaround after 10 red candles in a row.

Free L2: http://www.otcmarkets.com/stock/Bfar/quote

BFAR way undervalued.

On March 25, 2011, China Northern Pharmacy Holding Group Limited, a wholly-owned subsidiary of BioPharm Asia, Inc. (the “Company”), entered into an agreement to transfer all of the outstanding shares of its subsidiary Tonghua S&T Medical & Pharmacy Company Limited (“PHARMACY”) and its subsidiary Yunnan Silin Pharmaceutical Company Limited (“Silin”) to City Well International Limited for RMB 200 million, or approximately $30.5 million, based upon prevailing exchange rates.

Source : http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7821458

If we can trust all numbers and the Entry into a Material Definitive Agreement as of March 25, 2011, we come up with
Cash and cash equivalents $ 15,407,736
+ cash of Sale of its subsidiary Tonghua S&T Medical & Pharmacy Company Limited (“PHARMACY”) and its subsidiary Yunnan Silin Pharmaceutical Company Limited (“Silin”) of approximately $30.5 M
That´s total approximately $45.9M

Current mkt cap is only 7.00M

Market Value $7,000,000 a/o Apr 14, 2011
Shares Outstanding 50,000,000 a/o Aug 13, 2010  

 

New shortvolume for BFAR from today

Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market



20110414|BFAR|427483|0|688954|O
20110413|BFAR|487787|0|646493|O
20110412|BFAR|363012|0|594138|O
20110411|BFAR|450100|0|665233|O
20110408|BFAR|335900|0|482422|O
20110407|BFAR|599182|0|904480|O
20110406|BFAR|329335|0|441071|O
20110405|BFAR|98787|0|145607|O
20110404|BFAR|222027|0|254827|O
20110401|BFAR|217160|0|336900|O


Source: Finra
ShortVolume: 3530773
TotalVolume: 5160125